share_log

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

6-K:Sarclisa诱导治疗显著改善符合移植条件的新诊断多发性骨髓瘤患者的无进展生存期
美股SEC公告 ·  08/13 06:10
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息